Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study

Table 2 Treatment-emergent AEs occurring in ≥10% of patients in either ADT group (safety sample)

AE, %	Bupropion plus aripiprazole (n = 46)	SSRI/SNRI plus aripiprazole (n = 242)
Fatigue	26.1	23.6
Somnolence	21.7	18.2
Akathisia	17.4	23.6
Headache	17.4	15.3
Increased appetite	15.2	11.2
Insomnia	15.2	15.7
Arthralgia	13.0	3.3
Irritability	13.0	3.7
Middle insomnia	13.0	2.5
Upper respiratory tract infection	13.0	10.7
Erectile dysfunction	12.5	2.6
Anxiety	10.9	11.2
Asthenia	10.9	3.7
Back pain	10.9	5.4
Dry mouth	10.9	10.3
Nausea	10.9	11.6
Restlessness	10.9	12.4
Salivary hypersecretion	10.9	3.7
Tremor	10.9	8.7
Dizziness	8.7	10.3
Weight increased	8.7	19.0

ADT, antidepressant treatment; AE, adverse event; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

ISSN: 1756-0500